In a 13-year-old boy who developed a purpuric rash and bilateral lower-extremity edema after acute tonsillitis treated with cefuroxime, suspected Henoch‑Schönlein purpura, what is the appropriate management?

Management of Suspected Henoch-Schönlein Purpura in a 13-Year-Old

In this 13-year-old boy with purpuric rash and bilateral lower-extremity edema following acute tonsillitis, the primary management is supportive care with close monitoring for renal involvement, while corticosteroids should be reserved only for severe gastrointestinal symptoms or significant renal disease. 1

Immediate Assessment and Monitoring

Confirm the diagnosis by identifying palpable purpura (which this patient has) plus at least one of the following: diffuse abdominal pain, arthritis/arthralgia, or renal involvement (hematuria and/or proteinuria). 1 The bilateral lower extremity edema and post-infectious timing support HSP as the diagnosis.

Obtain baseline laboratory studies immediately:

• Urinalysis to detect hematuria and proteinuria (renal involvement occurs in 20-100% of cases) 1, 2
• Blood pressure measurement (hypertension can occur) 3
• Serum creatinine and BUN to assess renal function 1
• Complete blood count and coagulation studies to exclude other causes 1

Discontinue Cefuroxime

Stop the cefuroxime immediately, as medications can trigger HSP, and the acute tonsillitis has already been treated for 3 days. 2, 4 The rash may represent either HSP triggered by the streptococcal infection or a drug reaction contributing to the vasculitis.

Primary Management Strategy

Most cases are self-limited and require only supportive care. 1 The average disease duration is 4 weeks, and approximately 90% of cases occur in children aged 2-10 years, though this 13-year-old falls within the acceptable range. 1

Supportive measures include:

• Adequate hydration and rest 1
• NSAIDs for joint pain (if no contraindications and normal renal function) 1
• Elevation of affected limbs to reduce edema 1
• Observation for gastrointestinal complications including intussusception 3, 1

Corticosteroid Use: When and How

Current evidence does NOT support universal corticosteroid treatment for all HSP patients. 1 This is a critical point, as corticosteroids do not prevent or reduce the incidence of nephropathy. 1

Consider oral corticosteroids (prednisone 1-2 mg/kg/day) ONLY if:

• Severe gastrointestinal pain is present 1, 2
• Gastrointestinal hemorrhage occurs 1
• Severe scrotal involvement develops 1

Do NOT use corticosteroids prophylactically to prevent renal involvement, as early steroid treatment does not reduce the incidence or severity of nephropathy in children with HSP. 1

Renal Monitoring Protocol

Renal involvement is the most important prognostic factor determining morbidity and mortality in HSP. 1 Approximately 2% of children with HSP progress to renal failure. 2

Implement the following monitoring schedule:

• Weekly urinalysis for the first month 1
• Monthly urinalysis for 3-6 months after disease onset 1
• Blood pressure checks at each visit 1
• Serum creatinine if proteinuria or hematuria develops 1

If significant proteinuria develops (>3 months duration):

• Consider ACE inhibitor or angiotensin receptor blocker to prevent secondary glomerular injury 1
• Add corticosteroids for severe nephritis 1
• Refer to pediatric nephrology for possible renal biopsy 1, 5

Management of Severe Renal Disease

For rare life-threatening forms or severe renal compromise (ISKDC grade VI), consider:

• Methylprednisolone pulse therapy 2, 5
• Immunosuppressive drugs (cyclophosphamide, azathioprine) 2
• Plasma exchange 2, 5
• Polyclonal immunoglobulin therapy 2
• Tonsillectomy in refractory cases with persistent nephrotic syndrome 5

Common Pitfalls to Avoid

Do not assume the cefuroxime is treating HSP – antibiotics have no role in HSP management unless there is documented bacterial infection requiring treatment. 1 The tonsillitis was the trigger, not an ongoing infection requiring continued antibiotics.

Do not delay renal monitoring – failure to detect early nephropathy can lead to insufficient long-term monitoring and progression to chronic kidney disease. 3, 1

Do not use corticosteroids routinely – this is a common error, as steroids do not prevent the most serious complication (nephropathy) and expose patients to unnecessary side effects. 1

Prognosis and Follow-Up

Most cases have an excellent outcome, with complete resolution within 4 weeks. 1 However, long-term follow-up is essential because persistent hypertension and end-stage kidney disease, though rare, can occur. 1

Arrange follow-up:

• Weekly for the first month to monitor disease activity 1
• Monthly for 3-6 months to detect late renal involvement 1
• Annual blood pressure and urinalysis for at least 1 year after resolution 1